BioNTech Is Riding A Wave Of COVID-19 Vaccine Demand, But How Long Will It Last?
Company Will Earn Nearly $20bn In 2021
Executive Summary
Booster shots could maintain Comirnaty sales in 2022, but a sharp decline is expected in follow years – and so BioNTech needs a long-term growth plan.
You may also be interested in...
J.P. Morgan Day 2: What's Next For Pharma, From Alzheimer's To Omicron
Daily notebook from the virtual J.P. Morgan Healthcare Conference: Alzheimer's rivals Roche and Lilly address their attempts at a different launch for their anti-amyloid therapies than Biogen's Aduhelm. GSK is buoyed by sotrovimab's efficacy against Omicron, BioNTech looks to the future of mRNA and Sanofi, Amgen and AbbVie defend their growth strategies.
J.P. Morgan Day 2: What's Next For Pharma, From Alzheimer's To Omicron
Daily notebook from the virtual J.P. Morgan Healthcare Conference: Alzheimer's rivals Roche and Lilly address their attempts at a different launch for their anti-amyloid therapies than Biogen's Aduhelm. GSK is buoyed by sotrovimab's efficacy against Omicron, BioNTech looks to the future of mRNA and Sanofi, Amgen and AbbVie defend their growth strategies.
BioNTech Deal Shows Pfizer Is Reinvesting COVID-19 Windfall In mRNA
The companies’ third vaccine-development deal shows how COVID cash has also led mRNA-focused companies to beef up their organic pipelines amid talk of a merger wave.